Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension

Preparation by combinative technology

Zenab Attari, Amita Bhandari, P. C. Jagadish, Shaila Lewis

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The purpose of this study was to develop nanosuspension based on combinative technology to enhance the intestinal absorption of Olmesartan medoxomil (OLM), a potent antihypertensive agent with limited oral bioavailability. Two combinative approaches were employed and then characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied using non-everted rat intestinal sac model. Optimal OLM nanosuspension was prepared by a combination of ball milling and probe sonication using stabilizer, Poloxamer 407. The formula exhibited particle size of 469.9 nm and zeta potential of -19.1 mV, which was subjected to ex vivo studies. The flux and apparent permeability coefficient in intestine from OLM nanosuspension was higher than the plain drug, thereby suggesting better drug delivery.

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalSaudi Pharmaceutical Journal
Volume24
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Intestinal Absorption
Technology
Poloxamer
Sonication
Particle Size
Pharmaceutical Preparations
Antihypertensive Agents
Biological Availability
Intestines
Permeability
Olmesartan Medoxomil

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{f71713577c2a4e8595fa02803f2bced6,
title = "Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology",
abstract = "The purpose of this study was to develop nanosuspension based on combinative technology to enhance the intestinal absorption of Olmesartan medoxomil (OLM), a potent antihypertensive agent with limited oral bioavailability. Two combinative approaches were employed and then characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied using non-everted rat intestinal sac model. Optimal OLM nanosuspension was prepared by a combination of ball milling and probe sonication using stabilizer, Poloxamer 407. The formula exhibited particle size of 469.9 nm and zeta potential of -19.1 mV, which was subjected to ex vivo studies. The flux and apparent permeability coefficient in intestine from OLM nanosuspension was higher than the plain drug, thereby suggesting better drug delivery.",
author = "Zenab Attari and Amita Bhandari and Jagadish, {P. C.} and Shaila Lewis",
year = "2016",
doi = "10.1016/j.jsps.2015.03.008",
language = "English",
volume = "24",
pages = "57--63",
journal = "Saudi Pharmaceutical Journal",
issn = "1319-0164",
publisher = "King Saud University",
number = "1",

}

Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension : Preparation by combinative technology. / Attari, Zenab; Bhandari, Amita; Jagadish, P. C.; Lewis, Shaila.

In: Saudi Pharmaceutical Journal, Vol. 24, No. 1, 2016, p. 57-63.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension

T2 - Preparation by combinative technology

AU - Attari, Zenab

AU - Bhandari, Amita

AU - Jagadish, P. C.

AU - Lewis, Shaila

PY - 2016

Y1 - 2016

N2 - The purpose of this study was to develop nanosuspension based on combinative technology to enhance the intestinal absorption of Olmesartan medoxomil (OLM), a potent antihypertensive agent with limited oral bioavailability. Two combinative approaches were employed and then characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied using non-everted rat intestinal sac model. Optimal OLM nanosuspension was prepared by a combination of ball milling and probe sonication using stabilizer, Poloxamer 407. The formula exhibited particle size of 469.9 nm and zeta potential of -19.1 mV, which was subjected to ex vivo studies. The flux and apparent permeability coefficient in intestine from OLM nanosuspension was higher than the plain drug, thereby suggesting better drug delivery.

AB - The purpose of this study was to develop nanosuspension based on combinative technology to enhance the intestinal absorption of Olmesartan medoxomil (OLM), a potent antihypertensive agent with limited oral bioavailability. Two combinative approaches were employed and then characterized. In vitro intestinal absorption of OLM nanosuspension and plain OLM was studied using non-everted rat intestinal sac model. Optimal OLM nanosuspension was prepared by a combination of ball milling and probe sonication using stabilizer, Poloxamer 407. The formula exhibited particle size of 469.9 nm and zeta potential of -19.1 mV, which was subjected to ex vivo studies. The flux and apparent permeability coefficient in intestine from OLM nanosuspension was higher than the plain drug, thereby suggesting better drug delivery.

UR - http://www.scopus.com/inward/record.url?scp=84926144210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926144210&partnerID=8YFLogxK

U2 - 10.1016/j.jsps.2015.03.008

DO - 10.1016/j.jsps.2015.03.008

M3 - Article

VL - 24

SP - 57

EP - 63

JO - Saudi Pharmaceutical Journal

JF - Saudi Pharmaceutical Journal

SN - 1319-0164

IS - 1

ER -